Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 25,900 shares at $145.91 ($3.9M) on 2024-06-05, disclosed to the SEC on 2024-06-07.
Scheduled sale ($3.9M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $145.91 | 900 | $131K | 3.3% |
| 2 | $147.78 | 700 | $103K | 2.6% |
| 3 | $148.57 | 1,800 | $267K | 6.8% |
| 4 | $149.35 | 300 | $45K | 1.1% |
| 5 | $151.07 | 2,840 | $429K | 10.9% |
| 6 | $151.07 | 2,840 |
| $429K |
| 10.9% |
| 7 | $151.76 | 3,902 | $592K | 15.1% |
| 8 | $151.76 | 3,902 | $592K | 15.1% |
| 9 | $152.90 | 2,437 | $373K | 9.5% |
| 10 | $152.90 | 2,437 | $373K | 9.5% |
| 11 | $153.71 | 400 | $61K | 1.6% |
| 12 | $154.86 | 1,721 | $267K | 6.8% |
| 13 | $154.86 | 1,721 | $267K | 6.8% |
| Total | $151.70 avg | 25,900 | $3.9M | 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |